

Modulant Biosciences

Company Overview

Modulant Biosciences is focused on identifying and advancing novel small molecules that modulate the assembly of aberrant multiprotein complexes (MPCs) that catalyze protein assembly within host cells. Viruses and chronic diseases such as cancer rely on aberrant assembly machines to cause disease. In vitro and in vivo studies have confirmed that Modulant compounds can stop the disease process and restore health. Because their compounds focus on host cells and aberrant assembly machines, they are exquisitely potent and safe for ingestion or injection.

Problem or Market Opportunity

Modulant's strategy is to develop products to the clinical stage and license out lead candidates to the top 10 animal health companies to advance these molecules. This involves answering five main questions: efficacy, safety, manufacturability, intellectual property, and market outlook. Once all these questions are adequately answered, Modulant will find a development and commercialization partner.

Technical & Competitive Advantage

Modulant is developing first-in-class molecules with host-directed cellular machinery modulation functions. From a technical perspective, these molecules often target novel pathways or mechanisms of action, providing opportunities to address previously untreatable or poorly managed diseases. By pioneering new therapeutic approaches, developers can potentially achieve greater efficacy and safety profiles than existing treatments.

Regulatory Strategy & Intellectual Property

Small molecules will go through FDA approval. The FDA approval process will be followed up by commercialization partners.

Key Milestones

Q/YYYY	Objective	Milestone Description
Q3 2024	Pre-Clinical Stage	Feline Infectious Peritonitis Caused by coronavirus in Cats: Development of a small molecule to treat FIP in Cats. We are completing the pre-clinical phase and will then enter the clinical phase.
Q4 2024	Development	Cancer: Development of a single small molecule to treat multiple cancers in dogs. Lead molecules are available and will then enter the clinical phase.
	Pre-Clinical Stage	Porcine Reproductive & Respiratory Syndrome Virus: Development of small molecule against PRRSv. The untreatable condition causes swine producers over \$600M in losses yearly. Modulant has developed small molecules to treat the condition.

Capitalization History

Year	Grant or Equity Type	Description	Amount
2023	Angel Investment	Consolidated Angel Funding into one round Incorporated Modulant Biosciences	
2024	Angel Investor	Angel invested funds to advance FIP program	\$500K
2024		Ongoing term sheet discussions to advance PRRS molecules with a leading animal health company.	

Current Round, Terms, and Use of Proceeds

An Angel investment of \$500,000 is being used to advance the FIP program. Partnership proceeds will be used to advance the PRRS program when materialized.

Key Team Members and Advisors

Dr. Thmoas Campi | Founder and CEO

Received his DVM and MPVM degrees from UC Davis. He worked for Elanco Animal Health, where he conducted poultry technical consulting, leadership roles in US and European regulatory affairs, and technology acquisitions. While at Elanco, he was Director of External Innovation, creating new business models for novel medicines for food and companion animals. Most recently, Tom was head of research and regulatory affairs at Huvepharma, where he led the first generic approval of Monensin.

Dr. Vishu Lingappa | Scientific Advisor

Holds a BS in Biology from Swarthmore College. a Ph.D. in Cell Biology from Rockefeller University, and obtained his MD from Cornell University Medical College, completed a residency in internal medicine at UC San Francisco, and is a Fellow of the AAAS.E

Dr. Sanjeev Anand | Chief Business Officer

Received his bachelor's and master's degrees in India and PhD in Virology and Molecular Biology from Western College of Veterinary Medicine, University of Saskatchewan, Canada. He brings over 20 years of R&D, Business Development, and Strategic Alliance Management experience in animal & human health, finance, marketing, bioinformatics, and vaccine manufacturing and has delivered multiple high-value projects to the pipeline. He was part of technology acquisition and external teams at Elanco Animal Health, part of the CIO team at Eli Lilly, and led BD at Dechra Veterinary before moving over to TechAccel as VP of Animal Health & Nutrition to advance early-stage technologies.